Trial Profile
A phase 2, multicenter, open-label study of CNTO 328 (anti-IL-6 monoclonal antibody) in combination with mitoxantrone versus mitoxantrone in subjects with metastatic hormone-refractory prostate cancer (HRPC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Siltuximab (Primary) ; Mitoxantrone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors Centocor
- 05 Oct 2021 This trial has been completed in France, according to European Clinical Trials Database.
- 04 Sep 2021 This trial has been completed in Spain, according to European Clinical Trials Database.
- 29 Jun 2012 Company added in the association field as reported by EudraCT.